Entrada Therapeutics (TRDA) News
NASDAQ: TRDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TRDA news summary
We found 8 recent headlines mentioning Entrada Therapeutics (TRDA): 2 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. TRDA is making an outsized move today, down 6.25% at $4.35, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Entrada Advised By DMC To Introduce Cohort 3 In Phase 1/2 For Duchenne Muscular Dystrophy", was published by Nasdaq on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Entrada Therapeutics headlines
- Entrada Advised By DMC To Introduce Cohort 3 In Phase 1/2 For Duchenne Muscular Dystrophy(RTTNews) - Clinical-stage biopharmaceutical company Entrada Therapeutics Inc. (TRDA) announced today that an independent safety Data Monitoring Committee (DMC) has recommended initiating a Cohort 3…NasdaqTRDA, BRK.A
- Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 StudyEntrada Therapeutics announces that an independent DMC recommends initiation of Cohort 3 at the dose of 15 mg/kg in the ELEVATE-45-201 study.GlobeNewswire
- Entrada Therapeutics Consensus Price Target Raised 24.03% to $20.81The average one-year price target for Entrada Therapeutics (NASDAQGM:TRDA) has been revised to $20.81 / share. This is an increase of 24.03% from the prior estimate of $16.78 dated November 6, 2026.…Nasdaq
- Entrada Therapeutics Reports Third Quarter 2026 Financial ResultsEntrada Therapeutics reports third quarter 2026 financial results and highlights recent business updates.GlobeNewswire
- Entrada Therapeutics Appoints Linea Aspesi as Chief People OfficerEntrada Therapeutics announces the appointment of Linea Aspesi as Chief People Officer.GlobeNewswire
- Noteworthy Thursday Option Activity: TRDA, JBS, MCRIAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Entrada Therapeutics Inc (Symbol: TRDA), where a total of 5,011 contracts have traded so…NasdaqTRDA, JBS, MCRI
- Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45Entrada Therapeutics announces positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45.GlobeNewswire
- Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 StudyEntrada Therapeutics announces that an independent DMC recommends initiation of Cohort 3 at the top dose of 18 mg/kg in the ELEVATE-44-201 study.GlobeNewswire